Results 131 to 140 of about 3,220 (195)

Beyond the Michaelis–Menten: Evaluation of a tQSSA‐Based IVIVE Approach for Predicting In Vivo Intrinsic Clearance From Hepatocyte Assays

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT The classical Michaelis–Menten model, under the standard quasi‐steady‐state approximation (sQSSA), is widely used in in vitro‐in vivo extrapolation (IVIVE) studies using hepatocyte or human liver microsomal (HLM) assays to predict intrinsic hepatic clearance (Clint,vitro$$ {\mathrm{Cl}}_{\operatorname{int},\mathrm{vitro}} $$).
Ngoc‐Anh Thi Vu, Yun Min Song, Sang Kyum Kim, Hwi‐yeol Yun, Soyoung Lee, Jae Kyoung Kim, Jung‐woo Chae   +6 more
wiley   +1 more source

Physiologically based pharmacokinetic modelling to predict artemether and lumefantrine exposure in neonates weighing less than 5 kg treated with artemether–lumefantrine to supplement the clinical data from the CALINA study

Tropical Medicine and Health
Background Evidence-based recommendations for malaria treatment in patients weighing 
Helen Gu, Nada Abla, Vinay Kumar Venishetty, Birgit Schoeberl, Julia Zack, Heidi J. Einolf   +5 more
doaj   +1 more source

Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Quantitative systems pharmacology (QSP) models offer a useful platform to integrate drug pharmacology with knowledge about biological mechanisms across multiple scales and data sources into a unified quantitative framework. This makes them invaluable to address many relevant questions in drug research and development.
Johannes Tillil, Wilhelm Huisinga, Jane Knöchel   +2 more
wiley   +1 more source

Integrated PBPK modelling for PFOA exposure and risk assessment

Environmental Research
Per- and polyfluoroalkyl substances (PFASs) pose significant public health concerns due to their environmental persistence, bioaccumulation, and ubiquitous presence in human biomonitoring (HBM) data, despite regulatory restrictions. This study establishes a deterministic pharmacokinetic model for perfluorooctanoic acid (PFOA), enabling the estimation ...
Achilleas Karakoltzidis, Spyros P. Karakitsios, Catherine Gabriel, Dimosthenis Α. Sarigiannis   +3 more
openaire   +2 more sources

Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Janus kinase (JAK) inhibitors were recently identified as promising drug candidates for repurposing in Alzheimer's disease (AD) due to their capacity to suppress inflammation via modulation of JAK/STAT signaling pathways. Besides interaction
Maria L. Faquetti, Laura Slappendel, Hélène Bigonne, Francesca Grisoni, Petra Schneider, Georg Aichinger, Gisbert Schneider, Shana J. Sturla, Andrea M. Burden   +8 more
doaj   +1 more source

Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling

Pharmaceutics
Background/Objective: Cabotegravir (CAB), available as an oral tablet and as a long-acting (LA) nanosuspension for intramuscular injection, is approved as a combination therapy for the treatment, and as a monotherapy for the prevention, of HIV-1 ...
Helen Tracey, Simon T. Bate, Susan Ford, Parul Patel, Jackie Bloomer, Aarti Patel, Kunal S. Taskar   +6 more
doaj   +1 more source

Validating Physiologically‐Based Pharmacokinetic Models Using the Continuous Ranked Probability Score: Beyond Being Correct on Average

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Physiologically‐based pharmacokinetic (PBPK) models have become increasingly popular for model‐informed drug development (MIDD) over the past decade. While several guidelines for model evaluation exist, these are by design often of a general and non‐specific nature. It is clear what steps should be carried out but not necessarily how.
Laurens Sluijterman, Marjolein van Borselen, Rick Greupink, Joanna IntHout   +3 more
wiley   +1 more source

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT A high number of poorly soluble compounds are being developed; thus, understanding the factors that influence their absorption is critical. Intestinal bile salts, which facilitate micelle‐mediated solubilization, are particularly important for drugs with low solubility and are reported to be highly variable.
Laura G. Al‐Amiry Santos, Sebastian Polak, Karen Rowland Yeo   +2 more
wiley   +1 more source

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real‐World Data

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bilirubin is a breakdown product of erythrocytes and plays a crucial role in elimination of heme‐containing proteins. After its synthesis in the reticuloendothelial system, unconjugated bilirubin is released into plasma and taken up into the liver.
Ahenk Zeynep Sayin, Lars Kuepfer
wiley   +1 more source

Albumin Levels Are Predictive of Cachexia‐Induced Time‐Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Cachexia is a metabolic condition that accelerates the clearance of monoclonal antibodies in cancer patients and is a known mechanism causing time‐dependent clearance. Successful anticancer treatment often ameliorates symptoms of cachexia, reducing the drug clearance over time especially in patients who respond. Serum albumin level is a common
Jeffrey R. Proctor, Harvey Wong
wiley   +1 more source